GEN Exclusives

More »

GEN News Highlights

More »
Apr 18, 2012

Valeant to Purchase Certain Assets from Atlantis Pharma in Mexico

  • Valeant Pharmaceuticals is acquiring certain assets from Atlantis Pharma, a branded generics pharmaceutical company located in Mexico. The acquired assets' total revenue in 2011 was approximately $26 million and is expected to deliver double-digit growth in 2012.

    Atlantis’ portfolio consists of therapeutics for gastrointestinal diseases, pain, and inflammatory disorders, and together bring in a total of $71 million. The transaction with Valeant is expected to close in the second quarter.

    "Atlantis Pharma's well-known brands in Mexico, and the potential to expand our export business to Central America and the Andean region, make this a strong addition to our current operations in Mexico," states J. Michael Pearson, chairman and CEO of Valeant. "The ability to combine these assets with our existing operations in Mexico should provide distinct commercial synergies for our overall business."

    Valeant Pharmaceuticals is a multinational specialty pharmaceutical company that develops, manufactures, and markets a range of products primarily in the areas of neurology, dermatology, and branded generics.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Children and Antipsychotic Drugs

Do you think children and adolescents with behavioral problems are overmedicated?